MeVis Medical Solutions AG
- WKN: A0LBFE
- ISIN: DE000A0LBFE4
- Land: Germany
Nachricht vom 27.08.2012 | 07:30
MeVis Medical Solutions AG: Upward trend stabilized in Q2 2012
|
MeVis Medical Solutions AG / Key word(s): Half Year Results/Interim Report MeVis' upward trend stabilized in Q2 2012 Significantly improved profitability and increased liquidity with slightly rising sales - Group sales grew moderately to EUR 6.9 million in the first six months (prev. year: EUR 6.7 million). - License and maintenance business increased, the maintenance business share remained constant at 43 %. - Earnings before interest and taxes (EBIT) climbed to EUR 1.3 million (prev. year: EUR 0.2 million). - Liquidity rose further to EUR 9.0 million (end of 2011: EUR 7.5 million). Bremen, August 27, 2012 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading provider of medical imaging software, today announced its results for the first half of 2012. Sales in the first half of 2012 amounted to EUR 6,878 k, 3 % above the first half of 2011 (EUR 6,688 k) with both license (+2 %) and maintenance (+3 %) business contributing to this growth. The share of maintenance business remained constant at 43 % of total sales in the first half of the year. Sales in the Digital Mammography segment went down slightly by 1 % to EUR 5,145 k compared to the strong first half of 2011 (prev. year: EUR 5,191 k). Sales in the Other Diagnostics segment developed positively, rising by 16 % to EUR 1,733 k (prev. year: EUR 1,497 k). Sales in the second quarter of 2012 came to EUR 3,241 k, corresponding to a 9 % increase year-on-year. In the first half of 2012, capitalization of development costs went up by 8 % to EUR 1,409 k compared to the previous year's period. Personnel expenses dropped by a total of 9 % year-on-year in both the second quarter and the first six months and amounted to EUR 4,422 k in the first half of the year. At the same time, other operating expenses could be reduced noticeably again by 19 % to EUR 1,158 k on account of the continuing cost savings measures. After depreciation and amortization of EUR 1,656 k (7 % down year-on-year), earnings before interest and taxes (EBIT) increased by around EUR 1.1 million - one of the main reasons being the cost savings measures − to EUR 1,256 k (prev. year: EUR 181 k) in the first half of the year. The EBIT margin rose steeply to 18 % as a result (prev. year: 3 %). The net financial result of EUR 254 k (prev. year: EUR -617 k) also improved considerably, with the results of operation of the Dutch investment Medis and the strong US dollar contributing to this development. Pre-tax earnings rose correspondingly by almost EUR 2 million to EUR 1,510 k in the period under review (prev. year: EUR -436 k). Taking into account income tax expenses of EUR 844 k, a figure on par with the previous year and which is still primarily influenced by non-cash deferred taxes, MeVis closed the first half of the current financial year with consolidated net profit of EUR 666 k (prev. year: -1,172 k). Earnings per share therefore amounted to EUR 0.39 (prev. year: EUR -0.68). Liquid funds increased again in the second quarter and amounted to EUR 9,037 k on June 30, 2012 (compared to EUR 7,749 k on March 31, 2012 and EUR 7,506 k on December 31, 2011). 'Following the positive first half of 2012, we are confirming our 2012 guidance in which we forecast Group sales to stabilize at the previous year's level. We expect the EBIT to rise slightly as a result of our improved cost position,' said Dr. Robert Hannemann, CFO of MeVis Medical Solutions AG. 'We also anticipate further positive liquidity from operating activities in 2012, whereby a purchase price payment of EUR 3.0 million as part of the acquisition of the 49% stake in MBS KG will be due for the last time this year, which will have a corresponding impact on liquidity.' 'We have successfully started implementing our strategic reorientation. During our visits, we reassured our industrial customers that we will be increasingly focusing our business activities on their needs,' added Marcus Kirchhoff, CEO of MeVis Medical Solutions AG. 'We have also started our internal restructuring process. We have, for instance, provided the first resources for developing the new strategic business field, online services, from which we expect medium-term growth.' The financial reports of the company can be downloaded at http://www.mevis.de/mms/Finanzberichte.html. End of Corporate News 27.08.2012 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
| Language: | English | |
| Company: | MeVis Medical Solutions AG | |
| Universitätsallee 29 | ||
| 28359 Bremen | ||
| Germany | ||
| Phone: | +49 421 224 95 0 | |
| Fax: | +49 421 224 95 11 | |
| E-mail: | ir@mevis.de | |
| Internet: | http://www.mevis.de | |
| ISIN: | DE000A0LBFE4 | |
| WKN: | A0LBFE | |
| Listed: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart | |
| End of News | DGAP News-Service |
| 182849 27.08.2012 |
Interaktiv
Weitere News
-
16.05.13 07:30
MeVis Medical Solutions AG: MeVis' profitabili ... -
13.05.13 15:18
MeVis Medical Solutions AG: Bekanntmachung der ... -
07.05.13 11:46
MeVis Medical Solutions AG -
26.04.13 07:30
MeVis Medical Solutions AG: MeVis' profitabili ... -
16.04.13 18:00
MeVis Medical Solutions AG: MeVis Medical Solu ...
Anleihe im Fokus
7,75% p.a. - Rendite aus Familienhand
– Zeichnungsstart: 23. Mai – Börse Frankfurt
– Zeichnung ab 1.000 Euro
– Laufzeit 5 Jahre
– WKN: A1TNA7
– 100% Rückzahlungskurs
GBC-Fokusbox
Syzygy AG: Aktie kaufen
Die nach den ersten drei Monaten des laufenden Jahres von Syzygy präsentierten Zahlen liegen im Rahmen unserer Erwartungen. Angesichts unserer unveränderten Prognosen behalten wir das bisherige Kursziel von 5 € bei und erneuern das Rating KAUFEN.
Event im Fokus
38. m:access Analystenkonferenz München
Datum: 06.06.2013
Zeit: 9:30 Uhr - 17.00 Uhr
Ort: Börse München
Der AKTIONÄR News

24. Mai 09:30 3 Extra-Chancen fernab von CoBa, Nokia, E.on & Co: 400 Prozent Gewinn ...
24. Mai 08:52 Chart-Check Metro: Aktie hebt nach Kaufsignal ab
24. Mai 08:32 Apple-Aktie: Verrückte Bewertung, überzogener Kurssturz
24. Mai 07:55 Deutsche Bank: Harte Kritik - Dividende besänftigt
24. Mai 07:39 DAX fester erwartet: Außerdem Amadeus Fire, Commerzbank, Daimler, ...
